Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.
Tian J, Shidyak A, Periyasamy SM, Haller S, Taleb M, El-Okdi N, Elkareh J, Gupta S, Gohara S, Fedorova OV, Cooper CJ, Xie Z, Malhotra D, Bagrov AY, Shapiro JI.
Hypertension. 2009 Dec;54(6):1313-20. Epub 2009 Nov 2.PMID: 19884563 [PubMed - in process]Related articles